Articles related to DEVICE/DRUG APPROVALS

The FDA’s approval of Zurzuvae (zuranolone) as the first oral treatment for postpartum depression represents a significant advancement in patient care. Physicians are encouraged to explore this new option, considering both its proven efficacy and accompanying warnings, to provide more accessible care for those struggling with this serious condition.

The recent FDA approval of cantharidin introduces a novel topical treatment for molluscum contagiosum in patients aged 2 and above, presenting a significant stride in dermatological solutions.

The landscape of Alzheimer’s treatment is evolving with the introduction of antiamyloid monoclonal antibodies. Here is some clinical guidance to stay at the forefront of patient care.

The FDA’s approval of the olaparib, abiraterone, and prednisone regimen for BRCA-mutated mCRPC, based on the PROpel trial, could significantly alter the treatment landscape. Learn more about this promising development in prostate cancer therapy.

The recent approval of epcoritamab for R/R DLBCL introduces a new pathway in treatment, offering substantial response rates and the potential for broader implementation beyond academic centers. Explore the detailed insights into the function, efficacy, and prospective implications of this novel therapy.

Suflave™, an osmotic laxative approved by the FDA for colon cleansing in adults, represents a significant development in colonoscopy preparation. Patients interested in a low-volume option with improved taste attributes will find Suflave to be a promising alternative.